<DOC>
	<DOCNO>NCT01416350</DOCNO>
	<brief_summary>This two part protocol ( Parts A B ) healthy volunteer evaluate pharmacokinetics/ pharmacodynamics ( PK/PD ) azithromycin investigate usefulness various biomarkers ( e.g. , Interleukin-10 ( IL-10 ) , Granulocyte macrophage colony-stimulating factor ( GM-CSF ) , mature dendritic cell ( MDC ) , without ex vivo lipopolysaccharide ( LPS ) stimulation ) marker macrolide anti-inflammatory activity . Part A randomized , open-label parallel group study evaluate PK/PD single azithromycin dose 250 1000 mg. Data Part A use ass dose result induction/inhibition various ex vivo biomarkers relative 250 mg dose azithromycin ( clinical dose use treatment neutrophil-induced inflammatory condition ) . This information guide range dos study first time human ( FTIH ) study new chemical entity . Part B repeat dose study treat subject Azithromycin ( 250 mg every day 3 week ) , dose approximates use treatment chronic neutrophil related inflammatory condition . This information provide insight whether biomarker effect change time repeat dose potential difference observe single repeat dos .</brief_summary>
	<brief_title>A Single Repeat Dose PK/PD Study Characterise Biomarker Response Healthy Subjects Treated With Azithromycin</brief_title>
	<detailed_description>This two part protocol ( Parts A B ) healthy volunteer evaluate pharmacokinetics/ pharmacodynamics ( PK/PD ) azithromycin investigate usefulness various biomarkers ( e.g. , IL-10 , GM-CSF , MDC , without ex vivo lipopolysaccharide ( LPS ) stimulation ) marker macrolide anti-inflammatory activity . Part A randomized , open-label parallel group study evaluate PK/PD single azithromycin dose 250 1000 mg. Data Part A use ass dose result induction/inhibition various ex vivo biomarkers relative 250 mg dose azithromycin ( clinical dose use treatment neutrophil-induced inflammatory condition ) . This information guide range dos study FTIH study new chemical entity . Part B repeat dose study treat subject Azithromycin ( 250 mg every day 3 week ) , dose approximates use treatment chronic neutrophil related inflammatory condition . This information provide insight whether biomarker effect change time repeat dose potential difference observe single repeat dos .</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<criteria>Male female 18 65 year age inclusive Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy Childbearing potential agree use one contraception method Body weight â‰¥ 50 kg body mass index ( BMI ) within range 18.5 30 kg/m2 ( inclusive ) Capable give write informed consent , include compliance requirement restriction Single QT duration correct heart rate Bazett 's formula ( QTcB ) &lt; 450 msec . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality A positive prestudy drug/alcohol screen A positive test HIV antibody History regular alcohol consumption within 6 month study The subject participate clinical trial receive investigational product within 3 month Exposure four new chemical entity within 12 month prior first dose day Use prescription nonprescription drug , include vitamin , herbal dietary supplement History sensitivity study medication , erythromycin , macrolide ketolide antibiotic Where participation study would result donation blood blood product excess 500 mL within 56 day period The subject donate blood 3 month prior study Pregnant female determine positive serum urine hCG test screen prior dose Lactating female Unwillingness inability follow procedure outline protocol Subject mentally legally incapacitate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>